leisure time -WSS

leisure time

author：entertainment 2025-09-30 01:01:16 - browse：37423

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： How to make Best Hospitals ratings actually useful for patients

focus

WSS

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Appeals court upholds limits to abortion pill

Australia’s approach to dialysis celebrates life

Congress needs to close a vaccine

STAT wants to know your pick for a great summer read or listen

FDA approves Moderna’s RSV vaccine, its second licensed product

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Medical leaders decry Supreme Court decision on affirmative action

ASCO Daily Recap: CAR

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Departing Stanford president retracts two papers

Hepatitis C has a cure — but many Americans still lack access to it

Study finds new variant for Parkinson’s in African populations

ChatGPT in medicine: STAT answers readers' burning questions

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Hepatitis C has a cure — but many Americans still lack access to it

Senators tussle over abortion against the backdrop of a presidential campaign

focus

Apellis safety probe of eye disease drug centers on injection needle

Senators tussle over abortion against the backdrop of a presidential campaign

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

'Little Tech' descents on D.C., wanting a say in how AI is regulated

UnitedHealth CEO's Medicaid comments send insurer stocks diving

knowledge

Wikipedia

focus

hotspot